Rayence Co

Rayence Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Rayence Co (228850.KQ) as of Nov 7, 2026 is -24.70. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -5.47 — a change of 351.23% (lower).

EV/EBITDA

-24.70

YoY

351.23%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Rayence Co is 2025 -24.70 . EV/EBITDA (Enterprise Value to EBITDA) of Rayence Co was 2024 -5.47 . It decreases by 351.23% lower compared to the previous year.

The Rayence Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
0.66 KRW
Jan 1, 2019
0.68 KRW
Jan 1, 2020
0.52 KRW
Jan 1, 2021
-0.70 KRW
Jan 1, 2022
-1.29 KRW
Jan 1, 2023
-2.26 KRW
Jan 1, 2024
-5.47 KRW
Jan 1, 2025
-24.70 KRW
The Rayence Co EV/EBITDA history
YEAREV/EBITDAYoY
-24.70+351.23%
-5.47+142.22%
-2.26+75.33%
-1.29+85.27%
-0.70-234.06%
0.52-23.94%
0.68+3.79%
0.66+4.08%
0.63-32.49%
0.94-80.39%
4.77-45.59%
8.77—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Rayence Co is -24.70 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Rayence Co changed from -5.47 to -24.70, representing a 351.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Rayence Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Rayence Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Rayence Co

All Key Metrics — Rayence Co